Unaudited Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common stock	Additional paid-in capital	Additional paid-in capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated other comprehensive income (loss)	Accumulated deficit	Accumulated deficit Cumulative Effect, Period of Adoption, Adjustment
Beginning balance (in shares) at Dec. 31, 2020			95,456,862
Beginning balance at Dec. 31, 2020	$ 94,071		$ 95	$ 395,347		$ 9,371	$ (310,742)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Common stock in connection with follow-on offering, net of issuance costs of $17,466 (in shares)			7,961,538
Issuance of Common stock in connection with follow-on offering, net of issuance costs of $17,466	500,034		$ 8	500,026
Stock-based compensation expense	21,379			21,379
Common stock issued under employee stock plans, net (in shares)			2,728,995
Common stock issued under employee stock plans	4,673		$ 3	4,670
Taxes paid related to net share settlement of equity awards	(731)			(731)
Unrealized loss on derivative instruments	(5,185)					(5,185)
Unrealized income on available for sale securities	5					5
Net loss	(35,656)						(35,656)
Ending balance (in shares) at Mar. 31, 2021			106,147,395
Ending balance at Mar. 31, 2021	578,590		$ 106	920,691		4,191	(346,398)
Beginning balance (in shares) at Dec. 31, 2020			95,456,862
Beginning balance at Dec. 31, 2020	94,071		$ 95	395,347		9,371	(310,742)
Ending balance (in shares) at Dec. 31, 2021			107,509,096
Ending balance at Dec. 31, 2021	$ 596,593	$ (22,147)	$ 108	1,018,005	$ (30,794)	6,083	(427,603)	$ 8,647
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting Standards Update [Extensible Enumeration]	Accounting Standards Update 2020-06 [Member]
Stock-based compensation expense	$ 35,998			35,998
Common stock issued under employee stock plans, net (in shares)			2,057,101
Common stock issued under employee stock plans	6,111		$ 2	6,109
Taxes paid related to net share settlement of equity awards	(28,825)			(28,825)
Unrealized loss on derivative instruments	(3,179)					(3,179)
Unrealized income on available for sale securities	(10)					(10)
Net loss	(48,763)						(48,763)
Ending balance (in shares) at Mar. 31, 2022			109,566,197
Ending balance at Mar. 31, 2022	$ 535,778		$ 110	$ 1,000,493		$ 2,894	$ (467,719)